• Recruiting

NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM

Updated: Sep 16

Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy

NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

MagnetisMM-4 Elranatamab (PF-06863135)

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma


Sponsor

Pfizer

 

ClinicalTrials.gov Identifier: NCT05090566

Official Title: A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

First Posted : October 25, 2021

Click here for details on Clinicaltrials.gov


Multiple Myeloma Clinical Trial | Pfizer (pfizerclinicaltrials.com)


You don’t have to take on multiple myeloma alone | Pfizer Clinical Trials

 

Elranatamab


Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613

 

Drug: Elranatamab + Nirogacestat

Drug: Elranatamab + lenalidomide + dexamethasone

 

Nirogacestat


Nirogacestat (Code C82383)

Nirogacestat

NIROGACESTAT

PF-03084014

gamma secretase inhibitor PF-03084014

 

Locations

United States, California

United States, Florida

United States, Illinois

United States, Massachusetts

Canada, Alberta

Canada, Ontario

 

RELATED POSTS

MagnetisMM-1

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1

Click here for details


MAGNETISMM-2

NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2

Click here for details


MagnetisMM-3

NCT04649359: Phase 2: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma - MagnetisMM-3

Click here for details


MagnetisMM-4

NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4

Click here for details


MagnetisMM-5

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5

Click here for details


MagnetisMM-7

NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7

Click here for details


MagnetisMM-8

NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8

Click here for details


MagnetisMM-9

NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9

Click here for details


NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Click here for details

Posts Archive